BioWorld - Wednesday, February 25, 2026
Breaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sector

BioWorld, Analysis and data insight
BioWorld, Analysis and data insight RSS Feed RSS

R&D money

Biopharmas increase their R&D spending in 2019, analysis finds

March 10, 2020
By Peter Winter
According to an analysis conducted by BioWorld of the fourth-quarter and year-end 2019 financial reports filed by the top 100 public biopharmaceutical companies ranked by market cap, and excluding big pharma companies, the amount that was invested in research and development (R&D) during the year increased 35% compared to the same period in 2018.
Read More
Dollar sign, downward arrow

Biopharma equities caught in vortex of oil crash and coronavirus fears

March 9, 2020
By Peter Winter
The financial markets were delivered a one-two punch March 9 – a plunge in oil prices along with fears that the coronavirus is continuing to spread unabated. As a result, the Dow Jones Industrial Average cratered 1,500 points in early trading after a brief halt with market circuit breakers kicking in. Biopharma equities did not escape the carnage, with the BioWorld Biopharmaceutical index trading down about 4% by market close, with the Dow closing down 7.8%.
Read More
Wall Street sign

Completed and pending biopharma IPOs in February 2020

March 6, 2020
Completed and pending initial public offerings by biopharma companies, including: 4D Molecular, Akeso, Beam, Bio-Thera, Continent, Frontier, Hutchison China Meditech, Imara, Immunotech, Innocare, NLS, Oric, Passage Bio, Revolution Medicines, Scilex, Shanghai Shenlian, Tasly.
Read More

Follow-on offerings of biopharma companies in February 2020

March 6, 2020
Follow-ons completed by biopharma companies, including: Adma, Adverum, Agile, Appili, Applied Genetic Technologies, Atyr, Avrobio, Axovant Gene, Bioxcel, Briacell, Can-Fite, Catalyst, Collegium, Deciphera, Diamedica, Eyepoint, Fortress, Intec, Kezar Life Sciences, Miragen, Moderna, Novan, Oramed, PDS, Phio, Polarityte, Rapt, Rockwell Medical, Salarius, Seelos, Theravance, Tonix, Xeris, Ziopharm, Zosano.
Read More

Other financings of public biotechnology companies in February 2020

March 6, 2020
Private placements and other private financings of public biopharma companies, including: Acerus, Adamis, Aeterna Zentaris, Agile, Algernon, Alimera, Aptorum, Arch, Armata, Avadel, Biomerica, Cidara, Cocrystal, Collegium, Collplant, Cortexyme, CTI, Curis, Daré, Enlivex, E-therapeutics, Genmab, Genprex, Hemostemix, Kali-Extracts, Lidds, Lipocine, Mereo, Moleculin, Navidea, Novacyt, Orphazyme, Outlook, Phio, Promis, Redhill, Redx, Revance, Revive, Spero, Syndax, Syros, Valneva, Vaxil, Xortx, Zelira.
Read More